Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JP-1366 Maintenance Therapy in Healed Erosive Esophagitis
NCT07732075Phase 3Not yet recruiting
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Aug 2026
- Primary completion
- Oct 2028
01
Overview
Phase 3, randomised, double-blind trial of zastaprazan in erosive esophagitis (EE) (2 arms), sponsored by Onconic Therapeutics Inc. Primary endpoint: Proportion of subjects with maintained healing of erosive esophagitis at 24 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
zastaprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT07732075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732075.